My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zealand Pharma

< Previous 1 2 3 Next >
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
From Zealand Pharma
Via GlobeNewswire
Total number of shares and voting rights in Zealand Pharma as of September 30, 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
From Zealand Pharma
Via GlobeNewswire
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in upcoming investor conferences in September 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
From Zealand Pharma
Via GlobeNewswire
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
From Zealand Pharma
Via GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces closing of collaboration and license agreement with Roche
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Three Months of 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
From Zealand Pharma
Via GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
From Zealand Pharma
Via GlobeNewswire
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the Full Year 2024
From Zealand Pharma
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.